KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Common Equity (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Common Equity for 18 consecutive years, with $31.4 billion as the latest value for Q1 2026.

  • For Q1 2026, Common Equity rose 6.93% year-over-year to $31.4 billion; the TTM value through Mar 2026 reached $31.4 billion, up 6.93%, while the annual FY2025 figure was $31.3 billion, 6.48% up from the prior year.
  • Common Equity hit $31.4 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $31.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $31.4 billion in Q1 2026 and bottomed at $19.9 billion in Q1 2022.
  • Average Common Equity over 5 years is $26.5 billion, with a median of $27.0 billion recorded in 2024.
  • Year-over-year, Common Equity skyrocketed 66.27% in 2022 and then increased 5.56% in 2025.
  • Regeneron Pharmaceuticals' Common Equity stood at $22.7 billion in 2022, then rose by 14.6% to $26.0 billion in 2023, then increased by 13.02% to $29.4 billion in 2024, then increased by 6.48% to $31.3 billion in 2025, then increased by 0.53% to $31.4 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $31.4 billion, $31.3 billion, and $31.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.